High IGFBP2 levels are not only associated with a better metabolic risk profile but also with increased mortality in elderly men

European Journal of Endocrinology

Volumn 167, Issue 1, 2012, Pages 111-117

  Van Den Beld, Annewieke W ^a,b   Blum, Werner F ^c,d   Brugts, Michael P ^a   Janssen, Joop A M J L ^a   Grobbee, Diederick E ^e   Lamberts, Steven W J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b GROENE HART HOSPITAL   (Netherlands)

^c LILLY DEUTSCHLAND GMBH   (Germany)

^d UNIVERSITY HOSPITAL GIESSEN   (Germany)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LIOTHYRONINE; SERUM ALBUMIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL;

AGED; ARTICLE; BODY MASS; BONE DENSITY; COMORBIDITY; FOLLOW UP; GRIP STRENGTH; HUMAN; INDEPENDENT LIVING; INSULIN SENSITIVITY; MALE; METABOLIC SYNDROME X; MORTALITY; OBSERVATIONAL STUDY; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BONE DENSITY; FOLLOW-UP STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MALE; METABOLIC SYNDROME X; METABOLOME; MUSCLE STRENGTH; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84862737661     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0160     Document Type: Article

References (44)

1. Carter CS, Ramsey MM & Sonntag WE. A critical analysis of the role of growth hormone and IGF-1 in aging and lifespan. Trends in Genetics 2002 18 295-301. (doi:10.1016/S0168-9525(02)02696-3)
2. Barbieri M, Bonafe M, Franceschi C & Paolisso G. Insulin/IGF-I- signaling pathway: an evolutionarily conserved mechanism of longevity from yeast to humans. American Journal of Physiology. Endocrinology and Metabolism 2003 285 E1064-E1071. (doi:10.1152/ajpendo.00296.2003)
3. Brugts MP, Ranke MB, Hofland LJ, van der Wansem K, Weber K, Frystyk J, Lamberts SW & Janssen JA. Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays. Journal of Clinical Endocrinology and Metabolism 2008 93 2539-2545. (doi:10.1210/jc.2007-2454)
4. Hwa V, Oh Y & Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocrine Reviews 1999 20 761-787. (doi:10.1210/er.20.6.761)
5. Baxter RC. Insulin-like growth factor binding proteins in the human circulation: a review. Hormone Research 1994 42 140-144. (doi:10.1159/000184186)
6. Jones JI & Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews 1995 16 3-34.
7. Jones JI, Gockerman A, Busby WH Jr, Wright G & Clemmons DR. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. PNAS 1993 90 10553-10557. (doi:10.1073/pnas.90.22.10553)
8. Perks CM, Vernon EG, Rosendahl AH, Tonge D & Holly JM. IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 2007 26 5966-5972. (doi:10.1038/sj.onc.1210397)
9. Baxter RC, Meka S & Firth SM. Molecular distribution of IGF binding protein-5 in human serum. Journal of Clinical Endocrinology and Metabolism 2002 87 271-276. (doi:10.1210/jc.87.1.271)
10. Firth SM, McDougall F, McLachlan AJ & Baxter RC. Impaired blockade of insulin-like growth factor I (IGF-I)-induced hypoglycemia by IGF binding protein-3 analog with reduced ternary complex-forming ability. Endocrinology 2002 143 1669-1676. (doi:10.1210/en.143.5.1669)
11. Jogie-Brahim S, Feldman D & Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocrine Reviews 2009 30 417-437. (doi:10.1210/er.2008-0028)
12. van den Beld AW, Blum WF, Pols HA, Grobbee DE & Lamberts SW. Serum insulin-like growth factor binding protein-2 levels as an indicator of functional ability in elderly men. European Journal of Endocrinology 2003 148 627-634. (doi:10.1530/eje.0.1480627)
13. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S & Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes/Metabolism Research and Reviews 1999 15 314-322. (doi:10.1002/(SICI)1520-7560(199909/10)15:5〈314::AID-DMRR56〉3.0. CO;2-E)
14. Clemmons DR, Snyder DK & Busby WH Jr. Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. Journal of Clinical Endocrinology and Metabolism 1991 73 727-733. (doi:10.1210/jcem-73-4-727)
15. Heald AH, Kaushal K, Siddals KW, Rudenski AS, Anderson SG & Gibson JM. Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Experimental and Clinical Endocrinology & Diabetes 2006 114 371-376. (doi:10.1055/s-2006-924320)
16. Wheatcroft SB, Kearney MT, Shah AM, Ezzat VA, Miell JR, Modo M, Williams SC, Cawthorn WP, Medina-Gomez G, Vidal-Puig A, Sethi JK & Crossey PA. IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 2007 56 285-294. (doi:10.2337/db06-0436)
17. Hu D, Pawlikowska L, Kanaya A, Hsueh WC, Colbert L, Newman AB, Satterfield S, Rosen C, Cummings SR, Harris TB & Ziv E. Serum insulin-like growth factor-1 binding proteins 1 and 2 and mortality in older adults: the Health, Aging, and Body Composition Study. Journal of the American Geriatrics Society 2009 57 1213-1218. (doi:10.1111/j.1532-5415.2009.02318.x)
18. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW & Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. American Journal of Epidemiology 2003 157 25-31. (doi:10.1093/aje/kwf160)
19. Guralnik JM, Seeman TE, Tinetti ME, Nevitt MC & Berkman LF. Validation and use of performance measures of functioning in a non-disabled older population: MacArthur studies of successful aging. Aging 1994 6 410-419.
20. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA & Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. Journal of Gerontology 1994 49 M85-M94. (Pubitemid 24100267)
21. Hamilton A, Balnave R & Adams R. Grip strength testing reliability. Journal of Hand Therapy 1994 7 163-170. (doi:10.1016/S0894-1130(12)80058-5)
22. Gotfredsen A, Jensen J, Borg J & Christiansen C. Measurement of lean body mass and total body fat using dual photon absorptiometry. Metabolism 1986 35 88-93. (doi:10.1016/0026-0495(86)90101-0)
23. Mazess RB, Barden HS, Bisek JP & Hanson J. Dual-energy X-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. American Journal of Clinical Nutrition 1990 51 1106-1112.
24. Folstein MF, Folstein SE & McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975 12 189-198. (doi:10.1016/0022- 3956(75)90026-6)
25. Blum WF & Breier BH. Radioimmunoassays for IGFs and IGFBPs. Growth Regulation 1994 4 (Suppl 1) 11-19.
26. Chen JW, Ledet T, Orskov H, Jessen N, Lund S, Whittaker J, De Meyts P, Larsen MB, Christiansen JS & Frystyk J. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. American Journal of Physiology. Endocrinology and Metabolism 2003 284 E1149-E1155. (doi:10.1152/ajpendo.00410.2002)
27. Cooper R, Kuh D & Hardy R. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. BMJ 2010 341 c4467. (doi:10.1136/bmj.c4467)
28. Shimasaki S & Ling N. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Progress in Growth Factor Research 1991 3 243-266. (doi:10.1016/0955-2235(91) 90003-M)
29. Blum WF, Horn N, Kratzsch J, Jorgensen JO, Juul A, Teale D, Mohnike K & Ranke MB. Clinical studies of IGFBP-2 by radioimmunoassay. Growth Regulation 1993 3 100-104. (Pubitemid 23131752)
30. Reeve JG, Schwander J & Bleehen NM. IGFBP-2: an important regulator of insulin-like growth factor action in human lung tumours? Growth Regulation 1993 3 82-84. (Pubitemid 23131745)
31. Schwander J & Mary JL. The RIA for IGFBP-2 in man - a meagre catch? Growth Regulation 1993 3 104-108. (Pubitemid 23131753)
32. Counts DR, Gwirtsman H, Carlsson LM, Lesem M & Cutler GB Jr. The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. Journal of Clinical Endocrinology and Metabolism 1992 75 762-767. (doi:10.1210/jc.75.3.762)
33. Smith WJ, Underwood LE & Clemmons DR. Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults. Journal of Clinical Endocrinology and Metabolism 1995 80 443-449. (doi:10.1210/jc.80.2.443)
34. Kassem M, Brixen K, Mosekilde L, Blum WF & Flyvbjerg A. Effects of growth hormone treatment on serum levels of insulin-like growth factors (IGFs) and IGF binding proteins 1-4 in post-menopausal women. Clinical Endocrinology 1998 49 747-756. (doi:10.1046/j.1365-2265.1998.00606.x)
35. Zapf J, Schmid C, Guler HP, Waldvogel M, Hauri C, Futo E, Hossenlopp P, Binoux M & Froesch ER. Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia. Journal of Clinical Investigation 1990 86 952-961. (doi:10.1172/JCI114797)
36. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sonksen PH, Tanaka T & Thorne M. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. Journal of Clinical Endocrinology and Metabolism 1998 83 382-395. (doi:10.1210/jc.83.2.382)
37. Strasser-Vogel B, Blum WF, Past R, Kessler U, Hoeflich A, Meiler B & Kiess W. Insulin-like growth factor (IGF)-I and -II and IGF-binding proteins-1, -2, and -3 in children and adolescents with diabetes mellitus: correlation with metabolic control and height attainment. Journal of Clinical Endocrinology and Metabolism 1995 80 1207-1213. (doi:10.1210/jc.80.4.1207)
38. Wheatcroft SB & Kearney MT. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends in Endocrinology and Metabolism 2009 20 153-162. (doi:10.1016/j.tem.2009.01. 002)
39. Rajaram S, Baylink DJ & Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocrine Reviews 1997 18 801-831. (doi:10.1210/er.18.6.801)
40. Arafat AM, Weickert MO, Frystyk J, Spranger J, Schofl C, Mohlig M & Pfeiffer AF. The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. Journal of Clinical Endocrinology and Metabolism 2009 94 5093-5101. (doi:10.1210/jc.2009-0875)
41. Eiseman JL, Guo J, Ramanathan RK, Belani CP, Solit DB, Scher HI, Ivy SP, Zuhowski EG & Egorin MJ. Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors. Clinical Cancer Research 2007 13 2121-2127. (doi:10.1158/1078- 0432.CCR-06-2286)
42. Akanji AO & Smith RJ. The insulin-like growth factor system, metabolic syndrome, and cardiovascular disease risk. Metabolic Syndrome and Related Disorders 2012 10 3-13. (doi:10.1089/met.2011.0083)
43. Padwal RS, Pajewski NM, Allison DB & Sharma AM. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ: Canadian Medical Association Journal 2011 183 E1059-E1066. (doi:10.1503/cmaj.110387)
44. Trepanowski JF, Canale RE, Marshall KE, Kabir MM & Bloomer RJ. Impact of caloric and dietary restriction regimens on markers of health and longevity in humans and animals: a summary of available findings. Nutrition Journal 2011 10 107. (doi:10.1186/1475-2891-10-107)